welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Sarepta Therapeutics and Jerry R. Mendell, M.D. to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program from the 23rd International Annual Congress of the World Muscle Society
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, and Jerry R. Mendell, M.D., Curran-Peters Chair of Pediatric Research and Professor of Pediatrics and Neurology, Nationwide Children’s Hospital and The Ohio State University; The Research Institute at Nationwide Children’s Hospital, will host a webcast conference call from the 23rd International Annual Congress of the World Muscle Society (WMS) in Mendoza, Argentina, on Thursday, October 4, 2018 at 7:00 a.m. Eastern Time / 8:00 a.m. local Argentina time. The call will focus on an update regarding Sarepta’s Duchenne muscular dystrophy (DMD) micro-dystrophin gene therapy program and will be led by Dr. Mendell, a renowned researcher in the field of DMD.
rareRelated
-
2018 JAR of Hope Green Carpet GalaSave the date for 4th Annual Gala on Oct...
-
Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB PatientsThe purpose of this study is to evaluate...
-
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular DystrophyAntisense Therapeutics today announced d...
-
Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential...Catabasis Pharmaceuticals, Inc., a clini...
-
Critical scientific aspects that make gene therapy viablehttps://player.vimeo.com/video/275297686...
-
L-citrulline and Metformin in Becker’s Muscular DystrophyThe purpose of the study is to compare t...
-
CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene ...CureDuchenne, a national venture phila...